Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome
A significant proportion of patients who survive coronavirus disease of 2019 (COVID-19) develop a constellation of life-altering symptoms that persist long after the initial infection has resolved. This post-COVID-19 syndrome may result from the development of autoreactive IgG antibodies that cause...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Kirja |
| Julkaistu: |
Compuscript Ltd,
2023-06-01T00:00:00Z.
|
| Aiheet: | |
| Linkit: | Connect to this object online. |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
| Hyllypaikka: |
A1234.567 |
|---|---|
| Nide 1 | Saatavissa |